NASDAQ:NXGL NEXGEL (NXGL) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free NXGL Stock Alerts $2.21 -0.08 (-3.49%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.20▼$2.2850-Day Range$1.97▼$2.9652-Week Range$1.40▼$3.14Volume7,462 shsAverage Volume16,956 shsMarket Capitalization$13.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get NEXGEL alerts: Email Address NEXGEL MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 2 Articles This WeekInsider TradingAcquiring Shares$150,002 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.27 out of 5 starsMedical Sector743rd out of 913 stocksSurgical & Medical Instruments Industry80th out of 95 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for NEXGEL. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.37% of the float of NEXGEL has been sold short.Short Interest Ratio / Days to CoverNEXGEL has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NEXGEL has recently decreased by 26.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNEXGEL does not currently pay a dividend.Dividend GrowthNEXGEL does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NXGL. Previous Next 2.5 News and Social Media Coverage News SentimentNEXGEL has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NEXGEL this week, compared to 0 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NEXGEL insiders have bought more of their company's stock than they have sold. Specifically, they have bought $150,002.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.15% of the stock of NEXGEL is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.21% of the stock of NEXGEL is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NEXGEL is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NEXGEL is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNEXGEL has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About NEXGEL Stock (NASDAQ:NXGL)NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Read More NXGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NXGL Stock News HeadlinesApril 21, 2024 | msn.comNEXGEL CEO to Spotlight Company at Planet MicroCap ShowcaseApril 18, 2024 | finance.yahoo.comNEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024April 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 17, 2024 | msn.comNEXGEL (NXGL) Price Target Decreased by 14.29% to 6.12April 4, 2024 | finance.yahoo.comABBV Mar 2025 180.000 putApril 3, 2024 | markets.businessinsider.comNexGel Inc: Sustained Buy Rating Amid Growth and Strategic PositivityApril 3, 2024 | msn.comNEXGEL's Engineered Growth: A Triumph in Operational Efficiency and Strategic PartnershipsApril 1, 2024 | globenewswire.comNEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-YearApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 31, 2024 | msn.comNEXGEL Announces Q4 and Full-Year 2023 Earnings Call DateMarch 27, 2024 | globenewswire.comNEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to HolidayMarch 25, 2024 | msn.comNEXGEL Sets Date for Q4 and Full-Year 2023 Earnings RevealMarch 21, 2024 | globenewswire.comNEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28thMarch 4, 2024 | globenewswire.comNEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12thFebruary 24, 2024 | msn.comNEXGEL (NXGL) Price Target Increased by 16.67% to 7.14February 23, 2024 | msn.comNEXGEL Raises Capital, Strengthens Balance Sheet Amid Growth OpportunitiesFebruary 21, 2024 | finance.yahoo.comNEXGEL Announces $975,000 Registered Direct Offering Led by InsidersJanuary 18, 2024 | finance.yahoo.comNEXGEL to Present at The Microcap Conference, January 30th through February 1stJanuary 9, 2024 | finance.yahoo.comNEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024December 11, 2023 | finance.yahoo.comNEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North AmericaDecember 7, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Neurocrine (NBIX)December 5, 2023 | finance.yahoo.comNEXGEL Acquires Kenkoderm Psoriasis Skincare LineNovember 27, 2023 | msn.comNexgel (NXGL) Price Target Increased by 20.00% to 6.12November 26, 2023 | finance.yahoo.comNEXGEL, Inc. (NASDAQ:NXGL): When Will It Breakeven?November 20, 2023 | insidermonkey.comNEXGEL, Inc. (NASDAQ:NXGL) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | msn.comNEXGEL GAAP EPS of -$0.10 beats by $0.02, revenue of $1.2M in-lineNovember 13, 2023 | finance.yahoo.comNEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-YearSee More Headlines Receive NXGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NEXGEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NXGL CUSIPN/A CIK1468929 Webnexgel.com Phone215-702-8550FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,160,000.00 Net Margins-77.19% Pretax Margin-77.96% Return on Equity-49.49% Return on Assets-30.50% Debt Debt-to-Equity Ratio0.10 Current Ratio1.98 Quick Ratio1.46 Sales & Book Value Annual Sales$4.09 million Price / Sales3.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book2.46Miscellaneous Outstanding Shares6,230,000Free Float4,537,000Market Cap$13.77 million OptionableNot Optionable Beta0.68 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Adam R. Levy (Age 61)CEO, President & Director Comp: $334.51kMr. Adam E. Drapczuk III (Age 48)Chief Financial Officer Comp: $131.04kMr. Gregory RobbVice President of OperationsKey CompetitorsBiotricityNASDAQ:BTCYPetVivoNASDAQ:PETVMicrobot MedicalNASDAQ:MBOTT2 BiosystemsNASDAQ:TTOOPAVmedNASDAQ:PAVMView All CompetitorsInsiders & InstitutionsNortheast Financial Group Inc.Bought 11,848 shares on 4/15/2024Ownership: 0.190%Scott Robert HenryBought 23,697 shares on 3/1/2024Total: $50,000.67 ($2.11/share)Adam E Drapczuk IIIBought 47,394 shares on 3/1/2024Total: $100,001.34 ($2.11/share)Steven Mark GlassmanBought 3,885 shares on 12/22/2023Total: $8,547.00 ($2.20/share)John Nachum SteinBought 2,500 shares on 9/26/2023Total: $4,900.00 ($1.96/share)View All Insider TransactionsView All Institutional Transactions NXGL Stock Analysis - Frequently Asked Questions How have NXGL shares performed in 2024? NEXGEL's stock was trading at $2.13 at the start of the year. Since then, NXGL stock has increased by 3.8% and is now trading at $2.21. View the best growth stocks for 2024 here. Are investors shorting NEXGEL? NEXGEL saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 17,700 shares, a drop of 26.6% from the March 31st total of 24,100 shares. Based on an average daily volume of 21,600 shares, the short-interest ratio is presently 0.8 days. Approximately 0.4% of the shares of the company are sold short. View NEXGEL's Short Interest. When is NEXGEL's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NXGL earnings forecast. How were NEXGEL's earnings last quarter? NEXGEL, Inc. (NASDAQ:NXGL) released its quarterly earnings results on Monday, April, 1st. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $1.08 million for the quarter. NEXGEL had a negative net margin of 77.19% and a negative trailing twelve-month return on equity of 49.49%. What guidance has NEXGEL issued on next quarter's earnings? NEXGEL issued an update on its first quarter 2024 earnings guidance on Monday, April, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.3 million-$1.3 million, compared to the consensus revenue estimate of $1.2 million. When did NEXGEL IPO? NEXGEL (NXGL) raised $14 million in an initial public offering on Wednesday, December 22nd 2021. The company issued 2,100,000 shares at a price of $6.83 per share. Maxim Group LLC acted as the underwriter for the IPO. Who are NEXGEL's major shareholders? NEXGEL's stock is owned by many different institutional and retail investors. Top institutional shareholders include Northeast Financial Group Inc. (0.19%). Insiders that own company stock include Adam E Drapczuk III, Adam R Levy, David Stefansky, Jerome B Zeldis, John Nachum Stein, Nachum Stein, Scott Robert Henry and Steven Mark Glassman. View institutional ownership trends. How do I buy shares of NEXGEL? Shares of NXGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NXGL) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NEXGEL, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
